A leading executive in the biopharma industry and MBA alumna has been appointed to the Alliance Manchester Business School Advisory Board.
Dr Sarah Holland is Chief Business Officer at Cureteq AG, a biotechnology and asset management company based in Switzerland. She originally completed her Manchester MBA in 1998 and has spent more than 30 years in the biopharma industry.
She said: “The Manchester MBA was a fantastic, enriching experience which gave me insights and learnings that I have drawn upon ever since. I am honoured to have the opportunity to contribute to such a wonderful institution”.
High profile roles
Sarah’s previous roles include being Chief Business Officer of VectivBio AG, as well as global head of licensing and head of R&D at Lonza, one of the world’s leading biopharma contract manufacturing and development organisations.
She also worked for Roche for more than a decade, where she drove a number of notable deals and led the M&A (Mergers & Acquisitions) assessment and integration team.
As well as working in Switzerland for many years, she has also held commercial roles in diagnostics, biotech and pharma in the UK and the Netherlands, and originally took her MBA at Manchester after winning a scholarship for women in management from the Guardian newspaper. Sarah was also Visiting Fellow at the School from 2001 to 2004.
Advisory Board
The AMBS Advisory Board, which is chaired by Damaris Albarran (Ken Lever will take over as Chair from August), advises the School’s leadership team on the development of the School's strategy. It supports with the development of corporate, institutional and governmental links and offers an external perspective on the School's products and services.
Professor Fiona Devine, Head of Alliance Manchester Business School said: “We are delighted to have Sarah join our Board, bringing her extensive skills and experience back to the School, many years after the completion of her MBA.”
